Safety of Rabivax-S for Pre-exposure Prophylaxis

Rabies Vaccine Adverse Reaction Clinical Trial

Official title:

Safety of Rabivax-S in Individuals Receiving Pre-exposure Prophylaxis (PrEP)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03741270
• Other study ID #: 18-13-EX
• Status: Completed
• Phase: Phase 4
• Start date: October 24, 2018
• Est. completion date: March 28, 2019

Study information

• Verified date: September 2019
• Source: Ross University School of Veterinary Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

People who are at frequent or continuous risk of exposure to rabies virus should be vaccinated against the disease (pre-exposure prophylaxis). This includes people who work with rabies virus in research or diagnostic laboratories or vaccine production facilities, veterinarians, staff, animal-control and wildlife workers in areas where rabies is endemic. Veterinary students in clinical placements and externships are included in this category. Currently, DVM students at Ross University School of Veterinary Medicine (RUSVM) are vaccinated against rabies in their 7th semester (final pre-clinical semester). Vaccinations are done by RUSVM Health Services using Rabivax-S, produced by the Serum Institute of India (study co-sponsors). Previously-unvaccinated students receive three injections of vaccine, on day 0, 7 and 21-28. The aim of the study is to generate additional data on safety and tolerability of Rabivax-S administered as pre-exposure prophylaxis to this population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 159
• Est. completion date: March 28, 2019
• Est. primary completion date: March 28, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

A DVM student registered at RUSVM will be eligible for inclusion in the study if the student is:

1. in the 7th semester of the DVM program, or

2. is in the 5th or 6th semester of the DVM program and is planning to undertake a veterinary externship in the following semester break that would require pre-exposure prophylaxis to rabies.

Exclusion Criteria:

A DVM student who meets the inclusion criteria will be excluded from the study if the student:

1. has previously received a dose of rabies vaccine, or

2. has any condition for which rabies vaccination is contra-indicated, or

3. does not provide informed consent for participation.

Related Conditions & MeSH terms

• Rabies
• Rabies Vaccine Adverse Reaction

Intervention

Biological:
• Rabivax-S
Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg). The intervention is administered by intramuscular injection of 1 mL reconstituted vaccine in the deltoid area of the upper arm, on days 0, 7 and 21 (or 28).

Locations

Country	Name	City	State
Saint Kitts and Nevis	Ross University School of Veterinary Medicine	Basseterre

Sponsors (2)

Lead Sponsor	Collaborator
Ross University School of Veterinary Medicine	Serum Institute of India Pvt. Ltd.

Country where clinical trial is conducted

Saint Kitts and Nevis, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with at least one solicited adverse event (AE) within 4 days after any dose	Based on the package insert for Rabivax-S, the following adverse events will be solicited: Local reactions (limited to the site of the injection): pain, erythema, oedema, pruritus and induration.; Systemic reactions: fever, shivering, malaise, asthenia, faintness, dizziness, headache, myalgia, arthralgia, nausea and abdominal pain.; Hypersensitivity or allergic reactions: anaphylaxis, urticaria, rash and erythema multiforme.	Through 4 days after each dose
Secondary	Number of unsolicited adverse events during 28 days after the first dose	Definitions of AEs and SAEs are taken from the OHRP's Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events.; AE means any untoward or unfavorable medical occurrence in a participant, including any abnormal sign, symptom, or disease, temporally associated with the subject's participation in the research, whether or not considered related to the subject's participation in the research.; A SAE is any AE temporally associated with the subject's participation in research that meets any of the following criteria: results in death; is life-threatening; requires inpatient hospitalization; results in a persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; or; any other AE that, based upon appropriate medical judgment, may jeopardize the subject's health and may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.	Through 28 days after the first dose given (day 0)
Secondary	Number of serious adverse events during 28 days after the first dose		Through 28 days after the first dose given (day 0)
Secondary	Number of participants with at least one solicited adverse event (AE) within 4 days after first dose		Through 4 days after first dose (days 0-3)
Secondary	Number of participants with at least one solicited adverse event (AE) within 4 days after second dose		Through 4 days after second dose (days 7-10)
Secondary	Number of participants with at least one solicited adverse event (AE) within 4 days after third dose		Through 4 days after second dose (days 21-24 or days 28-31)